Natera's New Cancer Trial to Use Signatera for Personalized Treatment
Portfolio Pulse from Benzinga Newsdesk
Natera, Inc. (NASDAQ:NTRA) announced a new gastroesophageal cancer trial, DECIPHER, which will use its Signatera™ test to guide patient selection and assess MRD clearance. The trial will enroll 25 patients in the UK and evaluate a HER2-directed antibody-drug conjugate in the adjuvant setting.
June 27, 2024 | 11:06 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Natera's new DECIPHER trial will use its Signatera™ test for personalized treatment in gastroesophageal cancer, potentially boosting the company's product adoption and revenue.
The DECIPHER trial's use of Signatera™ for personalized treatment in gastroesophageal cancer could lead to increased adoption of Natera's product, positively impacting revenue. The trial's success could also enhance Natera's reputation in the medical community.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100